摘要
目的观察普罗布考和辛伐他汀联合治疗对急性冠状动脉综合征(ACS)患者高敏C反应蛋白(hsCRP)和血脂的影响。方法将79例ACS患者随机分为单独治疗组(辛伐他汀20mg/d)和联合治疗组(普罗布考1g/d,辛伐他汀20mg/d)分别测量两组患者服药前和服药1个月时的血清hsCRP、血脂(TC、TG、LDL-C、HDL-C)水平。结果治疗1个月后两组患者血清hs-CRP、TC、TG、LDL-C、HDL-C水平均较入院时降低(P<0.01),但联合治疗组降低的幅度较单独治疗组大(P<0.05)。结论普罗布考和辛伐他汀联合治疗与单用辛伐他汀均能降低ACS患者血清hsCRP和血脂水平,可能起到抑制炎症反应、稳定冠状动脉粥样斑块的作用,加用普罗布考可能发挥进一步稳定斑块的作用。
[Objective] To investigate the effects of Probucol combined with Simvastatin and Simvastatin only on serum lipid and high-sensitivity C-reactive protein （hs-CRP） levels after 1 month. [Methods] 79 ACS patients were assigned to Simvastatin only group （20 mg/d of simvastatin, n =39） or combined therapeutic group （20 mg/d of Simvastatin and 1.0 g/d of Probucol, n =40） in a randomized study. The levels of serum lipid and hs-CRP were de- tected before and after treatment. [Results] The levels of serum lipid and hs-CRP were significantly decreased in Simvastatin only group and combined therapeutic group （P 〈0.01）, and those in combined therapy decreased even more markedly （P 〈0.05）. [Conclusions] Both Simvastatin alone and Simvastatin combined Probueol can decrease the levels of serum lipid and hs-CRP in patients with ACS, which may reduce inflammatory reaction and stabilize plaque. Simvastatin combined with Probueol may have stronger effect on stabilizing plaque than Simvastatin alone.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2008年第18期2696-2697,2700,共3页
China Journal of Modern Medicine
